Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Case Rep Pediatr ; 2020: 1929581, 2020.
Article in English | MEDLINE | ID: mdl-32181040

ABSTRACT

A two-and-one-half-year-old previously healthy female presented with a ten-week history of watery diarrhea, nonbilious and nonbloody emesis, and low-grade fevers. She was found to have severe hypoalbuminemia and hypogammaglobulinemia. Her symptoms persisted, and she became dependent on parenteral nutrition. Biopsies obtained during subsequent endoscopic and colonoscopic studies revealed findings consistent with collagenous gastroenterocolitis. She responded to an empiric course of prednisone, but her symptoms recurred shortly after transitioning to oral budesonide. After successful reinduction with intravenous prednisone, intramuscular methotrexate was initiated. She remained asymptomatic during a 15-month course of therapy, and she continued to do well clinically until approximately nine months after weaning off methotrexate. At that point, she experienced a recurrence of diarrhea, and repeat endoscopic evaluation confirmed collagenous colitis. This responded nicely to a short course of oral budesonide, and she has since remained asymptomatic and off any therapy.

2.
Curr Med Res Opin ; 33(7): 1261-1268, 2017 07.
Article in English | MEDLINE | ID: mdl-28420280

ABSTRACT

OBJECTIVE: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children. METHODS: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6-17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9 mg or 6 mg once daily for 8 weeks; in the maintenance study, patients in remission received budesonide 6 mg once daily for 12 weeks. The primary objective was assessment of safety, including glucocorticosteroid-related side effects and serum cortisol levels. Efficacy was assessed using the Pediatric Crohn's Disease Activity Index (PCDAI), and health-related quality of life (HRQoL) using the IMPACT-III questionnaire. RESULTS: In the induction study (n = 108), most adverse events were related to CD, commonly abdominal pain; possible glucocorticosteroid-related effects included acne and increased appetite but without significant weight gain. Subnormal morning cortisol levels were observed in 32 of 103 patients after 8 weeks. Budesonide reduced disease activity from baseline (mean ± standard deviation, 9.1 ± 8.5 vs. 19.1 ± 10.1, p < .001) with 58.1% of patients reaching remission (PCDAI <10); HRQoL improved (p < .001). In the maintenance study (n = 50), mean disease activity worsened (p = .047) with HRQoL unchanged (p = .33). CONCLUSIONS: Budesonide treatment was generally well tolerated, although the potential for adrenal suppression was noted. Budesonide was effective for induction of remission in children with mild-to-moderate CD but not for maintaining remission (ClinicalTrials.gov identifiers: NCT01444092, NCT01453946).


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Budesonide/administration & dosage , Crohn Disease/drug therapy , Abdominal Pain/drug therapy , Abdominal Pain/etiology , Acne Vulgaris/chemically induced , Adolescent , Anti-Inflammatory Agents/therapeutic use , Child , Female , Humans , Male , Quality of Life , Remission Induction
3.
J Pediatr Hematol Oncol ; 29(5): 323-6, 2007 May.
Article in English | MEDLINE | ID: mdl-17483711

ABSTRACT

Epstein-Barr virus (EBV) infection can be complicated by cholestatic jaundice and hemolytic anemia, although both complications rarely occur simultaneously. An 18-year-old female developed acute EBV infection complicated by cold agglutinin hemolysis and cholestasis. Corticosteroid and ursodeoxycholic acid were initiated but bilirubin peaked at 1297.47 micromol/L (75.7 mg/dL). Plasmapheresis was initiated and with the corticosteroids, resulted in resolution of extreme hyperbilirubinemia. The patient recovered rapidly, is healthy 2 years later and is neurologically intact. The early use of plasmapheresis with corticosteroids and ursodeoxycholic should be considered in EBV infections complicated by extreme hyperbilirubinemia to prevent the rare complication of adult-onset kernicterus.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Epstein-Barr Virus Infections/complications , Hyperbilirubinemia/therapy , Hyperbilirubinemia/virology , Plasmapheresis/methods , Acute Disease , Adolescent , Female , Humans , Hyperbilirubinemia/pathology , Sensitivity and Specificity , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...